CAS NO: | 2062-78-4 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
Storage | Store at -20°C |
M.Wt | 461.6 |
Cas No. | 2062-78-4 |
Formula | C28H29F2N3O |
Synonyms | NSC 170984,Orap,R 6238 |
Solubility | insoluble in H2O; insoluble in EtOH; ≥17.95 mg/mL in DMSO |
Chemical Name | 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one |
Canonical SMILES | FC1=CC=C(C(CCCN2CCC(N3C(NC4=C3C=CC=C4)=O)CC2)C5=CC=C(F)C=C5)C=C1 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Pimozide is a chemically novel, highly potent and orally long-acting neuroleptic dopamine receptors inhibitor [1].
Dopamine receptors belong to G protein-coupled receptor containing five subtypes termed D1, D2, D3, D4, and D5. Dopamine receptors have been involved in many physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement to hormonal regulation and hypertension. Pharmacological drugs targeting dopaminergic neurotransmission have been clinically used in several neurological and psychiatric disorders, such as schizophrenia, Parkinson's disease, Huntington's disease, bipolar disorder, attention deficit hyperactivity disorder (ADHD), and Tourette's syndrome [2].
In vitro: Pimozide displayed high affinity for dopamine receptors. The Ki values for D2, D3, and D4 were 2.4, 0.2, and 1.8 nM, respectively [3].
In vivo: In hungry rats, pimozide attenuated lever-pressing and running for food reward. Pimozide pretreatment attenuated acquisition of a lever-pressing habit motivated by food reward in a dose-dependent manner[4]. In 31 male Wistar rats self-administering cocaine, pimozide caused a dose-dependent (0.0625–0.5 mg/kg) acceleration of responding [5].
Clinical trials: Pimozide was effective in treating Tourette's syndrome and positive psychotic symptoms in schizophrenia. Results from studies ranging from clinical vignettes to controlled trials indicated that pimozide also ameliorated negative schizophrenic symptoms, treated monosymptomatic delusional psychosis resistant to other neuroleptics, and treated pain syndromes [6].
References:
[1] Janssen P A, Niemegeers C J, Schellekens K H, et al. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine[J]. Arzneimittel-Forschung, 1968, 18(3): 261-279.
[2] Beaulieu J M, Gainetdinov R R. The physiology, signaling, and pharmacology of dopamine receptors[J]. Pharmacological reviews, 2011, 63(1): 182-217.
[3] Burstein E S, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist[J]. Journal of Pharmacology and Experimental Therapeutics, 2005, 315(3): 1278-1287.
[4] Wise R A, Schwartz H V. Pimozide attenuates acquisition of lever-pressing for food in rats[J]. Pharmacology Biochemistry and Behavior, 1981, 15(4): 655-656.
[5] De Wit H, Wise R A. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine[J]. Canadian Journal of Psychology/Revue canadienne de psychologie, 1977, 31(4): 195.
[6] Opler L A, Feinberg S S. The role of pimozide in clinical psychiatry: a review[J]. Journal of Clinical Psychiatry, 1991.